BRMS1 performs an anti-tumor effect on renal cell carcinoma via inhibition of PI3K/AKT/mTOR signaling pathway.Published in:Journal of Hainan Medical University, 2019, v. 25, n. 16, p. 1By:Ya-nan Cong;Zhen-guo Wang;Lin ZhaoPublication type:Article